

Trigeminal Neuralgia - Pipeline Review, H1 2018

<https://marketpublishers.com/r/TD332489A81EN.html>

Date: February 2018

Pages: 54

Price: US\$ 2,000.00 (Single User License)

ID: TD332489A81EN

Abstracts

Trigeminal Neuralgia - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H1 2018, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Trigeminal Neuralgia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Trigeminal Neuralgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase

III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Trigeminal Neuralgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Trigeminal Neuralgia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Trigeminal Neuralgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Trigeminal Neuralgia - Overview
- Trigeminal Neuralgia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Trigeminal Neuralgia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Trigeminal Neuralgia - Companies Involved in Therapeutics Development
- Allergan Plc
- Biogen Inc
- InMed Pharmaceuticals Inc
- KPI Therapeutics Inc
- Merz Pharma GmbH & Co KGaA
- PixarBio Corp
- Trigeminal Neuralgia - Drug Profiles
- carbamazepine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GTX-201 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- incobotulinumtoxin A - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- INM-405 - Drug Profile
- Product Description
- Mechanism Of Action

R&D Progress

OLP-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vixotrigine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Trigeminal Neuralgia - Dormant Projects

Trigeminal Neuralgia - Product Development Milestones

Featured News & Press Releases

Sep 15, 2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016

Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch

Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs

Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016

Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a

Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY

Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia

Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy

Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study

Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802

Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study

Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802

Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Trigeminal Neuralgia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Trigeminal Neuralgia - Pipeline by Allergan Plc, H1 2018
Trigeminal Neuralgia - Pipeline by Biogen Inc, H1 2018
Trigeminal Neuralgia - Pipeline by InMed Pharmaceuticals Inc, H1 2018
Trigeminal Neuralgia - Pipeline by KPI Therapeutics Inc, H1 2018
Trigeminal Neuralgia - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2018
Trigeminal Neuralgia - Pipeline by PixarBio Corp, H1 2018
Trigeminal Neuralgia - Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Trigeminal Neuralgia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Allergan Plc

Biogen Inc

InMed Pharmaceuticals Inc

KPI Therapeutics Inc

Merz Pharma GmbH & Co KGaA

PixarBio Corp

I would like to order

Product name: Trigeminal Neuralgia - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/TD332489A81EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TD332489A81EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970